TRPV2 and triple-negative breast carcinoma: Elbaz et al. demonstrated how the activation of the TRPV2 channel via its agonist cannabidiol significantly increases the cellular uptake of doxorubicin, thus enhancing the sensitivity of triple-negative breast cancer cells to chemotherapy in vitro and in vivo [63].